Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Javelin Pharmaceuticals |
---|---|
Information provided by: | Javelin Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00548678 |
This study will assess platelet function and safety in healthy male volunteers following doses of intravenous diclofenac compared to oral diclofenac (Cataflam), intravenous ketorolac and oral aspirin.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: intravenous diclofenac sodium (DIC075V) Drug: ketorolac Drug: oral diclofenac (Cataflam) Drug: aspirin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety Study |
Official Title: | Open-Label, Randomized, Single-Dose, Four-Treatment Crossover Study to Evaluate Platelet Function in Healthy Adult Males After Administration of IV Diclofenac Sodium, Oral Diclofenac Potasssium, IV Ketorolac Tromethamine, and Acetylsalicylic Acid |
Enrollment: | 30 |
Study Start Date: | October 2007 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
intravenous diclofenac sodium
|
Drug: intravenous diclofenac sodium (DIC075V)
intravenous diclofenac sodium
|
B: Active Comparator
intravenous ketorolac
|
Drug: ketorolac
intravenous ketorolac
|
C: Active Comparator
oral diclofenac (Cataflam)
|
Drug: oral diclofenac (Cataflam)
oral diclofenac (Cataflam)
|
D: Active Comparator
oral aspirin
|
Drug: aspirin
oral aspirin
|
The primary objective is to evaluate platelet function following intravenous diclofenac, oral diclofenac (Cataflam), intravenous ketorolac and oral aspirin.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Comprehensive Phase One | |
Miramar, Florida, United States, 33025 |
Study Director: | Javelin Pharmaceuticals | Javelin Pharmaceuticals |
Responsible Party: | Javelin Pharmaceuticals ( Javelin Pharmaceuticals ) |
Study ID Numbers: | DFC-007 |
Study First Received: | October 22, 2007 |
Last Updated: | July 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00548678 History of Changes |
Health Authority: | United States: Food and Drug Administration |
diclofenac, platelet aggregation, ketorolac, aspirin |
Anti-Inflammatory Agents Cyclooxygenase Inhibitors Ketorolac Diclofenac Fibrinolytic Agents Cardiovascular Agents Healthy Fibrin Modulating Agents |
Aspirin Analgesics, Non-Narcotic Platelet Aggregation Inhibitors Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Ketorolac Tromethamine Antirheumatic Agents |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Hematologic Agents Ketorolac Physiological Effects of Drugs Diclofenac Enzyme Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents |
Aspirin Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Platelet Aggregation Inhibitors Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Ketorolac Tromethamine Central Nervous System Agents |